Drug intelligence / Profile preview

HGP0918

Development stage: Unknown
Lead developer: Hanmi Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

HGP0918 is a small molecule drug developed by Hanmi Pharmaceutical. It has been investigated primarily for the treatment of hyperlipidemias and other endocrinology and metabolic diseases. The drug has completed Phase 1 clinical trials, including studies evaluating its pharmacokinetics both alone and in combination with another investigational agent (HGP0816). Its precise mechanism of action, molecular target(s), and detailed pharmacological profile have not been publicly disclosed as of June 2025. There is no evidence that it is a biosimilar or generic version of an existing approved therapy[1][2].

Beyond the preview

Go deeper on HGP0918.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HGP0918.

Explore the full profile